Is 'male menopause' a real medical condition or a TikTok trend?

What's this video probably claiming?

Based on the hashtags #mensmenopause and #andropause, this creator is almost certainly walking her audience through the idea that men experience a hormonal decline analogous to female menopause. She's probably describing symptoms like fatigue, low libido, mood changes, and brain fog as signs of falling testosterone, and framing andropause as an underdiagnosed condition men should be pushing their doctors to test for. That framing isn't wrong, exactly, but it carries some baggage. The term 'male menopause' gets used interchangeably with 'andropause' and 'late-onset hypogonadism,' and those are not the same thing clinically. Videos in this category also tend to lean heavily on the idea that testosterone replacement therapy is the straightforward fix, which glosses over a genuinely complicated diagnostic picture. The advocacy angle, getting men to talk openly about hormonal health, is legitimate. The simplification of the underlying biology is where things tend to go sideways.

What does the science actually show?

Men do experience a gradual testosterone decline with age, roughly 1-2% per year after age 30, according to data from the Massachusetts Male Aging Study (Feldman et al., 2002, Journal of Clinical Endocrinology and Metabolism). But this is not menopause. Female menopause involves a relatively abrupt cessation of ovarian function and a dramatic hormonal drop. Male testosterone decline is slow, highly variable between individuals, and not universal. The European Male Aging Study (Wu et al., 2010, NEJM) found that only about 2% of men aged 40-79 met criteria for late-onset hypogonadism, defined as low testosterone combined with specific sexual symptoms. That's a far cry from the broad symptom clusters circulating on social media. Fatigue, low mood, and weight gain have dozens of causes. Attributing them to andropause without proper lab work, specifically total testosterone, free testosterone, LH, and FSH, is a diagnostic shortcut that can miss real pathology like thyroid dysfunction, sleep apnea, or depression.

Where does the social media noise diverge from clinical reality?

The biggest divergence is in the symptom list. TikTok content on andropause typically presents a broad, relatable menu of complaints, brain fog, reduced drive, belly fat, irritability, that almost any middle-aged man could check off. That's effective content, but it's not a diagnostic tool. The Endocrine Society's 2018 clinical practice guidelines state clearly that symptoms alone are insufficient to diagnose hypogonadism and that at least two fasting morning testosterone measurements below 300 ng/dL are required before considering TRT. Another friction point is the menopause framing itself. It implies a standardized hormonal event, which creates patient expectations that don't match what labs often show. Many men presenting with these symptoms have testosterone levels in the low-normal range, where the evidence for TRT benefit is weak. The TRAVERSE trial (Lincoff et al., 2023, NEJM) provided useful cardiovascular safety data on TRT, but it also reinforced that TRT is a treatment for confirmed hypogonadism, not a general wellness upgrade for anyone feeling tired at 45.

What should you actually know?

If this video gets men to actually talk to a doctor and get labs done, that's a net positive. Hypogonadism is genuinely underdiagnosed, and men are historically bad at seeking care for anything that feels vague or emotional. But the information ecosystem around andropause is cluttered with supplement companies and optimization clinics that have financial incentives to expand the diagnostic tent as wide as possible. Before anyone pursues TRT, a proper workup matters. That means ruling out secondary causes, checking LH and FSH to distinguish primary from secondary hypogonadism, and ideally getting a referral to an endocrinologist or urologist rather than a direct-to-consumer hormone clinic. TRT is not without risk. The TRAVERSE trial showed a higher rate of pulmonary embolism and atrial fibrillation in the testosterone group compared to placebo. For men with confirmed hypogonadism, the benefit-risk calculation is often favorable. For men chasing optimization, the math looks different.